

Target	
Mechanism of Action	<ul style="list-style-type: none"> Targeted protein degradation platform technology
Indication - Primary	<ul style="list-style-type: none"> Various cancer-related targets
Indication - Expansion	<ul style="list-style-type: none"> Antitumor agent
Route of Administration	<ul style="list-style-type: none"> -
Competitive Advantage	<ul style="list-style-type: none"> Unique platform technology acquisition
Data Files	<ul style="list-style-type: none"> Acquired novel CRBN ligand Validated targeted protein degradation (Ikaros/Aiolos) Confirmed AR and BRD4 degradation using novel TD technology
IP Status	<ul style="list-style-type: none"> Patent filing
Collaboration Model	<ul style="list-style-type: none"> Collaborative research
Contact (Science)	<ul style="list-style-type: none"> Jae Du Ha (jdha@kRICT.re.kr, +82-42-860--7072) Jong Yeon Hwang (jyhwang@kRICT.re.kr, +82-42-860--7045)
Contact (Licensing)	<ul style="list-style-type: none"> Moon Geun Jung (Technology marketing office, mgjung@kRICT.re.kr, +82-42-860-7746) Choon-gil Kim (Technology marketing office, joykim@kRICT.re.kr, +82-42-860-7079) Kyung Sun Choi (Technology marketing office, chanian@kRICT.re.kr, +82-42-860-7076)